AIDS Treat News. 1997 Feb 7;(No 264):4-5. Unique Identifier : AIDSLINE
A study is seeking more than 2,000 volunteers for a phase III trial of
GS 840 (also called adefovir dipivoxil, or bis-POM PMEA), to test
whether the drug, taken orally once a day, can increase survival of
persons with advanced HIV, and also whether it can prevent the
development of CMV disease. GS 840 is known to be active against
cytomegalovirus (CMV), hepatitis B, HHV6 (human herpes virus 6),
Epstein-Barr virus, and to have some modest activity against HIV. In
this study, participants will continue their regular antiviral
treatments, and add GS 840 or placebo once a day. More information can
be obtained by calling the AIDS Clinical Trials Information Service or
Gilead Sciences Medical Information.
*Acquired Immunodeficiency Syndrome/DRUG THERAPY *Anti-HIV
Agents/THERAPEUTIC USE
www.aegis.org